RESMED INC (RMD)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

RMD - RESMED INC

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 1.18
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

ResMed is the global market leader in providing devices for the treatment of sleep apnoea and chronic pulmonary disease. Formed in Australia in 1989 the company listed on the ASX in 1999 and is also listed on the NYSE. ResMed's head office is in San Diego, California.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$24.95

06 Dec
2023

0.220

OPEN

$24.80

0.89%

HIGH

$24.98

3,107,942

LOW

$24.67

TARGET
$32.228 29.2% upside
Franking for last dividend paid out: 0%
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CYC . EBR . EMV . EYE . FPH . HLA . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . SOM . TRJ . UBI . VHT . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
RMD: 1
Title FY24
Forecast		 FY25
Forecast
EPS (cps) 112.0 xxx
DPS (cps) 29.4 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio 22.3 xxx
Dividend Yield 1.2% xxx
Div Pay Ratio(%) 26.3% xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 0.98%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 1.10

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 08/11 - ex-div 5.35c (franking 0%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx90.9
DPS All xxxxxxxxxxxxxxx21.9
Sales/Revenue xxxxxxxxxxxxxxx6,278.2 M
Book Value Per Share xxxxxxxxxxxxxxx421.9
Net Operating Cash Flow xxxxxxxxxxxxxxx1,030.7 M
Net Profit Margin xxxxxxxxxxxxxxx21.25 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx24.06 %
Return on Invested Capital xxxxxxxxxxxxxxx18.15 %
Return on Assets xxxxxxxxxxxxxxx15.20 %
Return on Equity xxxxxxxxxxxxxxx24.06 %
Return on Total Capital xxxxxxxxxxxxxxx23.14 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx468.8 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx48 M
Long Term Debt xxxxxxxxxxxxxxx2,326 M
Total Debt xxxxxxxxxxxxxxx2,373 M
Goodwill - Gross xxxxxxxxxxxxxxx4,162 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx342 M
Price To Book Value xxxxxxxxxxxxxxx7.78

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx199.2 M
Capex % of Sales xxxxxxxxxxxxxxx3.17 %
Cost of Goods Sold xxxxxxxxxxxxxxx2,839 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx1,727 M
Research & Development xxxxxxxxxxxxxxx428 M
Investments - Total xxxxxxxxxxxxxxx221 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.8

No. Of Recommendations

6
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

xx/xx/xxxx

3

xxxxxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

30/10/2023

1

Add

$32.74

31.22%

ResMed's 1Q results were broadly in line with Morgans expectations. Mask growth was considered a highlight though device growth was somewhat tempered on tough comparisons to prior periods.

Mask growth was supported by resupply and new patient setups at all-time highs, explain the analysts. A 20bps quarter-on-quarter improvement for gross product margin (GPM) was an additional positive, in Morgans view.

On the topic de jour, management noted that while weight-loss drugs could reduce the total addressable market by around -15% in the worst case scenario, the market remains both large and under-penetrated at less than 10%.

The target falls to $32.74 from $36.95 and the Add rating is unchanged.

FORECAST
Morgans forecasts a full year FY24 dividend of 27.92 cents and EPS of 120.87 cents.
Morgans forecasts a full year FY25 dividend of 29.88 cents and EPS of 137.01 cents.

Citi

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >

RMD STOCK CHART

FNArena News on RMD

1
November In Review: Equities Up As Bond Yields Slide

Dec 06 2023 - Australia
2
Rudi’s View: Bear&Bull Market To Continue (?) In 2024

Dec 06 2023 - Rudi's View
3
Rudi’s View: All-Weather Portfolio In 2023

Nov 29 2023 - Rudi's View
4
Rudi’s View: Quality In Stocks; What Is It Good For?

Nov 22 2023 - Rudi's View
5
Rudi’s View: Between Perception & Reality

Nov 15 2023 - Rudi's View

Latest Medical Equipment & Devices News

1
Dr Boreham’s Crucible: Pro Medicus

Oct 23 2023 - Australia
2
Dr Boreham’s Crucible: Cyclopharm

Oct 09 2023 - Small Caps
3
Dr Boreham’s Crucible: Painchek

Sep 11 2023 - Small Caps
4
Margins Signal Integral Diagnostics Recovery

Sep 07 2023 - Australia
5
ResMed: Finding A Base?

Aug 15 2023 - Technicals
6
August Turns ResMed Into Nigel NoMates

Aug 09 2023 - Australia
7
Dr Boreham’s Crucible: Lumos Diagnostics

Jun 19 2023 - Small Caps
8
Fisher & Paykel Healthcare: Lower Margin, Higher Spending

May 30 2023 - Australia
9
Dr Boreham’s Crucible: Impedimed

May 08 2023 - Small Caps
10
Treasure Chest: ResMed’s Benevolent Monopoly

May 01 2023 - Treasure Chest